Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma

PHASE1UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

October 31, 2010

Conditions
Multiple Myeloma
Interventions
DRUG

Fluphenazine HCl

Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.

Trial Locations (3)

15232

NOT_YET_RECRUITING

University of Pittsburgh Cancer Institute Hillman Cancer Center, Pittsburgh

19104

RECRUITING

Hospital of the University of Pennsylvania, Philadelphia

78229

RECRUITING

Cancer Therapy and Research Center at the UT Health Sciences Center at San Antonio, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Immune Control

INDUSTRY